Lilly to pay Beam up to USD 600m for rights to experimental heart disease treatments
Lilly will pay Beam USD 200m upfront and make a USD 50m equity investment in the company, the companies said Tuesday in a statement. Lilly, which has deep expertise in heart disease, will pay as much as an additional USD 350m if the programs hit certain goals.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.